Dr. José R. Carlo Izquierdo
Contact Info
Education
Degree: M.D. UPR, School of Medicine, 1978
UPR, Pre-Med-Special Advanced Placement Program- 1972-974
INTERNSHIP: Charity Hospital, New Orleans, Louisiana State University, 1978-79
RESIDENCY: Neurology, Louisiana State University, 1979-1982
FELLOWSHIP: Neuromuscular Diseases, University of Southern California Neuromuscular Center (W.K. Engel, Director), 1982-83
SPECIALTY: Neurology
SUBSPECIALTY: Neuromuscular Diseases, Electrodiagnostic Medicine, Pain Medicine
ACADEMIC POSITIONS
Associate Professor, UPR, School of Medicine 1994-2001.
Assistant Professor, UPR, School of Medicine 1986-1994.
Assistant Professor, Neuropediatric Section, San Juan, City Hospital, 1984-1994
Associate Director, Neurology Training Program, UPR, School of Medicine, 1988-1992.
Chancellor, UPR, Medical Sciences Campus, July 2002-September 2009.
Acting Chancellor, UPR, Medical Sciences Campus, March 2001- July 2002.
Member, University of Puerto Rico Administrative Board, March 2001-2009.
Clinical Instructor, University of Southern California, School of Medicine, 1982-1983
GRANTS & PROJECTS
On-going
University of Puerto Rico Medical Sciences Campus, Patient Services, Muscular Dystrophy Association “MDA Care Center” Grant, Muscular Dystrophy Association, Grant Period 2016-2019.
PI: Carlo, Jose R.
Longitudinal Study of the Relationship between Impairment, Activity Limitation, Participation and Quality of Life in Persons with Confirmed Duchenne Muscular Dystrophy (DMD). Cooperative Internation Neuromuscular Research Group (CINRG). Funded DOD, Muscular Dystrophy Association. Completed.
Clinical Trial of Coenzyme Q 10 and ACE Inhibitors in Duchenne Muscular Dystroph. Cooperative Internation Neuromuscular Research Group (CINRG). Funded DOD, Muscular Dystrophy Association. Completed.
3. Tadalafil in Duchenne Muscular Dystrophy, Sponsor Eli Lilly, 2014-on going, Clinical Trial, PI- site director.
PI Carlo, J
.5G12RR003051-22
RCMI Multidisciplinary Collaborative Research Program NATIONAL CENTER FOR RESEARCH RESOURCES 01-SEP-1997/31-JUL-2011
The proposed goal of the Program for the next five years is to continue the development of competitive research on the Medical Sciences Campus, by focusing on the development of a strong infrastructure for conducting multidisciplinary collaborative research studies through the establishment of clusters of excellence in health disparities affecting the Puerto Rican population, minority institution research support
m Carlo, J 5P20RR011126-13
30-SEP-1997/30-JUN-2010
Medical Sciences Campus Clinical Research Development NATIONAL CENTER FOR RESEARCH RESOURCES
Capacity Building and Infrastructure support for Clinical Research. Support for the RCMI Clinical Research center at the University of Puerto Rico Medical Sciences Campus.
m Carlo, J
5S21MD001830-03
30-SEP-2005/31-AUG-2008
NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES
Capacity Advancement in Research Infrastructure: U Puerto Rico School of Dentistry
The goal of this is to advance (via stable endowment funding) the health disparities research infrastructure and capacity of the University of Puerto Rico School of Dentistry (UPRSD) and the Graduate School of Public Health (UPRGSOPH) for the conduct, collaboration, and promotion of scientifically meritorious research on Health Disparities, while developing the “pipeline” of new minority researchers.
PUBLICATIONS
D; Tadalafil DMD study Group.Neur010gy. 2017 Oct T 811-1820 doi: 10.1212/WNL.0000000000004570. Epub 2017 sep 29. PMID: 28972192 As Co-investigator with the CINRG (Cooperative International Neuromuscular Research Group
TCTEXIDI is a genetic modifier of disease progression in Duchenne muscular dystrophy.
Spitali PI, ZaharievqJ2, Bohringu_$3, Hiller M4, Chaouch A5,6, Roos A5, Scotton C7, Claustres M8, Bello L9,10,
McDonald CMI 1, Hoffman EP9; CINRG Investigators, Koeks Z12, Eka Suchiman H13, Cirak Scoto
Ml 4, Reza M5, Hoen PAC4, Niks EH 12, TuffelY-Giraud S8, Lochmiifler H5, 17,18, Feriini Al, Muntoni FM, 19, Aartsma-Rus A4,5. Eur J Hum Genet. 2020 Jan 2. doi: 10.10381s41431-019-0563-6.
Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy. Conrado DJ, et al; Duchenne Muscular Dystrophy Regulatory Science Consortium (D-RSC). J Pharmacokinet
Pharmacodyn. 2019 May 24. doi: 10.1007/s10928-019„09642-7. [Epub ahead of print] PMID.• 31127458
Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids.
McDonald CMI, Gordish-Dressman H2, Henricson EK3, Duong T4, Joyce NC3, Jhawar S3, Leinonen M5, Hsu F2, Connolly AM6, Cnaan A2, Abresch RT3; CINRG investigators fox PubMed. Neuromuscul Disord. 2018 doi: 10.1016/j.nmd.2018.07.004. Epub 2018 Aug 29.
Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.
McDonald CMI, Henricson EK2, Abresch RT2, Duong T3, Joyce NC2, Hu F4, Clemens PR5, Hoffman EP6, Cnaan A4, Gordish-Dressman H4; CINRG Investi ators. Lancet. 2018 Feb doi: 10.1016/S014067360 7)32160-8. Epub 2017 Nov 22.
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy.
Hoganh MW1,2, Houweling PJI Thomas KCI, Gordish-Dressman H6, Bello L6,7•, Cooperative International Neuromuscular Research Groum(CJNRG), Pegoraro E7, Hoffman
EP6, I-lead S13, North IQ, Nat Commun. 2017 Jan PMID: 28139640 PMCID: PMC5290331 DOI: 10.1038/ncomms14143